These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18975095)

  • 1. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
    Boiko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EY; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaitsev KA; Kostenko EV
    Neurosci Behav Physiol; 2008 Nov; 38(9):933-6. PubMed ID: 18975095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
    Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of stalevo in the treatment of patients with Parkinson's disease].
    Kretova AS; Lyubimov AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):35-8. PubMed ID: 25591514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
    Boĭko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EIu; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaĭtsev KA; Kostenko EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):21-4. PubMed ID: 18427455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(2):73-6. PubMed ID: 16614538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long term experience with Stalevo in Szeged, Hungary].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2009 May; 62(5-6):178-80. PubMed ID: 19579666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entacapone/levodopa/carbidopa combination tablet: Stalevo.
    Drugs R D; 2003; 4(5):310-1. PubMed ID: 12952501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].
    Fedorova NV; Levin OS; Smolentseva IG; Kulua TK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):39-46. PubMed ID: 17069061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
    Eggert K; Skogar O; Amar K; Luotonen L; Kuoppamäki M; Leinonen M; Nissinen H; Oertel W
    J Neural Transm (Vienna); 2010 Mar; 117(3):333-42. PubMed ID: 20013007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
    Liashchenko EA; Skripkina NA; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa/carbidopa/entacapone in Parkinson's disease.
    Seeberger LC; Hauser RA
    Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
    Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
    Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacotherapy of motor manifestations in late stages of Parkinson's disease].
    Bogdanov RR; Kotov SV; Kunitsyna AN; Turbina LG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 1):21-5. PubMed ID: 21183918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
    Levin OS; Smolentseva IG; Fedorova NV; Chigir' IP; Dokadina LV; Makhnev SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):27-34. PubMed ID: 18833115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should levodopa dose be reduced when switched to stalevo?
    Linazasoro G; Kulisevsky J; Hernández B;
    Eur J Neurol; 2008 Mar; 15(3):257-61. PubMed ID: 18215153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.